TY - JOUR
T1 - Arsenic trioxide
T2 - Its use in the treatment of acute promyelocytic leukemia
AU - Sanz, Miguel A.
AU - Lo-Coco, Francesco
PY - 2006
Y1 - 2006
N2 - Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myeloid leukemia and is characterized by a unique genetic abnormality and frequent association with a severe hemorrhagic diathesis. An arsenic trioxide formulation for intravenous infusion has been developed and is currently licensed for the induction of remission and consolidation in adult patients with relapsed/refractory APL. Several studies have shown that arsenic trioxide is highly effective in the treatment of relapsed/refractory patients with APL, achieving remission rates of >80%, high rates of molecular remission, and durable periods of disease-free survival. Furthermore, recent studies indicate that arsenic trioxide may also have a role in the treatment of newly diagnosed patients, either as a single agent or in combination with tretinoin. These studies suggest a synergistic effect when arsenic trioxide and tretinoin are administered in combination, reducing the time to complete remission and rapidly reducing promyelocytic leukemia/retinoic acid receptor-α protein transcripts. Arsenic trioxide is generally well tolerated with a manageable adverse-event profile. The most common adverse events occur during the induction cycle and are often associated with the APL differentiation syndrome. Other common adverse events include leucocytosis, prolongation of the QT/corrected QT interval, peripheral neuropathy, neutropenia, thrombocytopenia, hyperglycemia, and hypokalemia.
AB - Acute promyelocytic leukemia (APL) represents approximately 10-15% of all adult cases of acute myeloid leukemia and is characterized by a unique genetic abnormality and frequent association with a severe hemorrhagic diathesis. An arsenic trioxide formulation for intravenous infusion has been developed and is currently licensed for the induction of remission and consolidation in adult patients with relapsed/refractory APL. Several studies have shown that arsenic trioxide is highly effective in the treatment of relapsed/refractory patients with APL, achieving remission rates of >80%, high rates of molecular remission, and durable periods of disease-free survival. Furthermore, recent studies indicate that arsenic trioxide may also have a role in the treatment of newly diagnosed patients, either as a single agent or in combination with tretinoin. These studies suggest a synergistic effect when arsenic trioxide and tretinoin are administered in combination, reducing the time to complete remission and rapidly reducing promyelocytic leukemia/retinoic acid receptor-α protein transcripts. Arsenic trioxide is generally well tolerated with a manageable adverse-event profile. The most common adverse events occur during the induction cycle and are often associated with the APL differentiation syndrome. Other common adverse events include leucocytosis, prolongation of the QT/corrected QT interval, peripheral neuropathy, neutropenia, thrombocytopenia, hyperglycemia, and hypokalemia.
UR - http://www.scopus.com/inward/record.url?scp=33846851758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846851758&partnerID=8YFLogxK
U2 - 10.2165/00024669-200605030-00005
DO - 10.2165/00024669-200605030-00005
M3 - Article
AN - SCOPUS:33846851758
VL - 5
SP - 183
EP - 191
JO - American Journal of Cancer
JF - American Journal of Cancer
SN - 1175-6357
IS - 3
ER -